EICHORCondition: Acute Ischemic Stroke · Sponsor: Basking Biosciences, Inc.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset. Participants will be randomized to receive one dose of either the investigational drug or placebo and will be followed for 90 days. A total of 228 patients are planned in this study.
This description comes directly from the study's public registry record.
Program Director · 9196184721 · snelson@baskingbiosciences.com
Always discuss trial participation with your own doctor first.
| HonorHealth Bob Bove Neuroscience Institute | Scottsdale, Arizona, United States | Recruiting |
| Mills Peninsula Medical Center | Burlingame, California, United States | Withdrawn |
| MemorialCare Long Beach Medical Center | Long Beach, California, United States | Withdrawn |
| California Pacific Medical Center | San Francisco, California, United States | Withdrawn |
| Pacific Neurosciences Institute at Saint John's Physician Partners | Torrance, California, United States | Recruiting |
| Baptist Health Medical Center | Jacksonville, Florida, United States | Terminated |
| Henry Ford Hospital | Detroit, Michigan, United States | Recruiting |
| Washington University in St. Louis | St Louis, Missouri, United States | Recruiting |
| Cooper University Hospital | Camden, New Jersey, United States | Recruiting |
| WakeMed | Raleigh, North Carolina, United States | Recruiting |
| The Ohio State University | Columbus, Ohio, United States | Recruiting |
| ProMedica Toledo Hospital | Toledo, Ohio, United States | Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06226805